CN1679537A - Single nitrate isosorbide sodium chloride injection - Google Patents
Single nitrate isosorbide sodium chloride injection Download PDFInfo
- Publication number
- CN1679537A CN1679537A CN 200410030825 CN200410030825A CN1679537A CN 1679537 A CN1679537 A CN 1679537A CN 200410030825 CN200410030825 CN 200410030825 CN 200410030825 A CN200410030825 A CN 200410030825A CN 1679537 A CN1679537 A CN 1679537A
- Authority
- CN
- China
- Prior art keywords
- sodium chloride
- injection
- isosorbide mononitrate
- chloride injection
- isosorbide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A liquid sodium chloride injection of isosorbide mononitrate for treating coronary heart disease and angina pectoris is prepared from isosorbide mononitrate and sodium chloride. It can quickly take its high curative effect.
Description
Technical field
The present invention relates to a kind of injection, particularly a kind of treatment coronary heart disease and anginal isosorbide mononitrate sodium chloride injection belong to field of medicaments.
Background technology
Isosorbide mononitrate is a kind of treatment coronary heart disease and anginal common drug, at first by the development of German Boehringer Mannheim Gmb.h company, and in listing in 1981, through clinical use for many years, determined curative effect.Its main mechanism of action is expansion of veins capacitance vessel and Peripheral resistance blood vessel, heart front and back load is descended, and reduce myocardial oxygen consumption.This medical instrument has the bioavailability height, and individual variation is little, long half time, and characteristics evident in efficacy are better than sorbitrate and nitroglycerin to coronary heart disease and anginal prevention.
At present, the dosage form of isosorbide mononitrate has tablet, capsule etc., after the oral administration, blood drug level rises to 400ng/ml rapidly, substantially exceeds minimum useful effect dosage (100ng/ml), causes side effect such as patient heavier headache occurs, feels sick, vomiting, circulatory collapse, incidence rate reaches about 14%, and when taking for a long time, toleration often appears, lessen the curative effect.
Recent studies show that the coronary dilating of isosorbide mononitrate acts on antianginal, and particularly anti-myocardial infarction aspect has important function.This is that under the normal condition, thick arteria coronaria only accounts for 5% of total hat resistance to the resistance of blood flow because the coronary dilating effect of such medicine mainly occurs in thick arteria coronaria, and its variation does not have obvious influence to coronary flow.But when coronary atherosclerosis caused the narrow and spasm of organic height, the ratio that its resistance accounts for coronary resistance obviously increased, and is the major reason that causes acute myocardial infarction.So the time thick arteria coronaria expansion be the important channel that prevents myocardial infarction.
Summary of the invention
The purpose of this invention is to provide a kind of can be more safe and reliable, act on isosorbide mononitrate sodium chloride injection rapidly.
Each components contents is among the every 100ml of injection provided by the present invention:
Isosorbide mononitrate 15～30mg
Sodium chloride 850～930mg
Preferably, each components contents is among the every 100ml of this injection:
Isosorbide mononitrate 20mg
Sodium chloride 886mg
Above-mentioned sodium chloride is as isoosmotic adjusting agent, the osmotic pressure of injection can be adjusted to close with the osmotic pressure of people's blood.
The preparation method of this injection can be according to the preparation method preparation of this area routine.
The clinical practice of this injection is in intravenous drip, and general dosage is 60～120 μ g/min, once a day.
The present invention is comparing following advantage with its tablet, capsule aspect the treatment acute myocardial infarction: (1) effect is reliable rapidly.Coronary spasm is removed more early in the acute myocardial infarction treatment, and its curative effect better.(2) can control heart rate effectively by adjusting intravenous drip speed, prevent that heart rate from accelerating and the side effect that causes.(3) be convenient to keep constant curative effect, remove fully until spasm.This injection is applied to when clinical, conditions of patients is eased rapidly and controls, and avoid the generation of other complication, is having more advantage than other dosage forms aspect quick-acting and the first aid.
The specific embodiment
The present invention is further illustrated below in conjunction with embodiment, but range of application of the present invention is not limited only to the following example.
Embodiment 1
Isosorbide mononitrate 15g
Sodium chloride 850g
Water for injection is an amount of
Preparation technology: isosorbide mononitrate and sodium chloride are dissolved in an amount of water for injection, add the injection active carbon, heated and boiled 10 minutes is filtered; Add to the full amount of water for injection, after the fill sterilization is made 1000 bottles, promptly.
Embodiment 2
Isosorbide mononitrate 18g
Sodium chloride 868g
Water for injection is an amount of
Preparation technology is with embodiment 1.
Embodiment 3
Isosorbide mononitrate 27g
Sodium chloride 905g
Water for injection is an amount of
Preparation technology is with embodiment 1.
Embodiment 4
Isosorbide mononitrate 30g
Sodium chloride 930g
Water for injection is an amount of
Preparation technology is with embodiment 1.
Claims (2)
1, a kind of isosorbide mononitrate sodium chloride injection is characterized in that each components contents is in every 100ml injection: isosorbide mononitrate 15～30mg; Sodium chloride 850～930mg.
2, injection according to claim 1 is characterized in that each components contents is in every 100ml injection: isosorbide mononitrate 20mg; Sodium chloride 886mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410030825 CN1679537A (en) | 2004-04-07 | 2004-04-07 | Single nitrate isosorbide sodium chloride injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410030825 CN1679537A (en) | 2004-04-07 | 2004-04-07 | Single nitrate isosorbide sodium chloride injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1679537A true CN1679537A (en) | 2005-10-12 |
Family
ID=35066560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410030825 Pending CN1679537A (en) | 2004-04-07 | 2004-04-07 | Single nitrate isosorbide sodium chloride injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1679537A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708157B (en) * | 2009-12-08 | 2011-06-22 | 鲁南制药集团股份有限公司 | Isosorbide mononitrate sodium chloride injection |
| CN104027329A (en) * | 2014-06-04 | 2014-09-10 | 回音必集团(江西)东亚制药有限公司 | Isosorbide dinitrate sodium chloride injection |
| CN106619499A (en) * | 2016-12-22 | 2017-05-10 | 扬子江药业集团南京海陵药业有限公司 | Preparation method of isosorbide mononitrate injection |
| CN106798723A (en) * | 2017-03-17 | 2017-06-06 | 山东鲁抗医药股份有限公司 | A kind of isosorbide mononitrate injection and preparation method thereof |
-
2004
- 2004-04-07 CN CN 200410030825 patent/CN1679537A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708157B (en) * | 2009-12-08 | 2011-06-22 | 鲁南制药集团股份有限公司 | Isosorbide mononitrate sodium chloride injection |
| CN104027329A (en) * | 2014-06-04 | 2014-09-10 | 回音必集团(江西)东亚制药有限公司 | Isosorbide dinitrate sodium chloride injection |
| CN104027329B (en) * | 2014-06-04 | 2015-04-15 | 回音必集团(江西)东亚制药有限公司 | Isosorbide dinitrate sodium chloride injection |
| CN106619499A (en) * | 2016-12-22 | 2017-05-10 | 扬子江药业集团南京海陵药业有限公司 | Preparation method of isosorbide mononitrate injection |
| CN106798723A (en) * | 2017-03-17 | 2017-06-06 | 山东鲁抗医药股份有限公司 | A kind of isosorbide mononitrate injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6795571B2 (en) | Intravenous administration of glybrid and other drugs | |
| CN101287457B (en) | Use of treprostinil to treat neuropathic diabetic foot ulcers | |
| TWI248816B (en) | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage | |
| JP2022009125A5 (en) | ||
| JP2004517148A (en) | Essential N-3 fatty acids in the treatment of heart dysfunction and heart failure | |
| US9283197B1 (en) | More potent and less toxic formulations of epinephrine and methods of medical use | |
| CN107412152B (en) | Dexmedetomidine hydrochloride injection composition | |
| CN1679537A (en) | Single nitrate isosorbide sodium chloride injection | |
| CN1663569A (en) | Fructose injection for cardiovascular medicine | |
| CN1663615A (en) | Fructose injection of antibiotic medicine | |
| CN100337629C (en) | Milrinone sodium chloride injection and production thereof | |
| Pasero | Intravenous lidocaine for acute pain treatment | |
| US20020193435A1 (en) | Nitroglycerin-menthol potentiation for treatment of angina | |
| CN1440287A (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and automatic neuropathies | |
| CN1062133C (en) | Medicine for treating hypertensional sickness | |
| CN109588698A (en) | A kind of functional food that preventing and treating mental disorder induced by alcoholism and drug and its preparation method | |
| CN1744896A (en) | Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist | |
| JPH0788300B2 (en) | Pharmaceutical composition containing epinin or a pharmaceutically acceptable salt thereof and use thereof | |
| CN106176693A (en) | One is used for treating angina pectoris Neulized inhalation preparation | |
| CN1047519C (en) | Nifedipine injection | |
| CN1666747A (en) | Fructose injection of anti-tumor drug | |
| CN1481798A (en) | Large capacity gingko damole injection and its preparation method | |
| CN1682715A (en) | Anti-anoxia medicinal composition | |
| Kelkar et al. | Special Surgical Situations and Diabetes Management: Part 1 | |
| Genunche-Dumitrescu et al. | The Sequential Treatment for Helicobacter Pylori Eradication as a First-Line Therapy in Type 2 Diabetic Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |